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 ABSTRACT
TBX2 is an oncogenic transcription factor known to drive breast cancer 
proliferation. We have identified the cysteine protease inhibitor Cystatin 6 (CST6) 
as a consistently repressed TBX2 target gene, co-repressed through a mechanism 
involving Early Growth Response 1 (EGR1). Exogenous expression of CST6 in TBX2-
expressing breast cancer cells resulted in significant apoptosis whilst non-tumorigenic 
breast cells remained unaffected. CST6 is an important tumor suppressor in multiple 
tissues, acting as a dual protease inhibitor of both papain-like cathepsins and 
asparaginyl endopeptidases (AEPs) such as Legumain (LGMN). Mutation of the CST6 
LGMN-inhibitory domain completely abrogated its ability to induce apoptosis in TBX2-
expressing breast cancer cells, whilst mutation of the cathepsin-inhibitory domain or 
treatment with a pan-cathepsin inhibitor had no effect, suggesting that LGMN is the 
key oncogenic driver enzyme. LGMN activity assays confirmed the observed growth 
inhibitory effects were consistent with CST6 inhibition of LGMN. Knockdown of LGMN 
and the only other known AEP enzyme (GPI8) by siRNA confirmed that LGMN was the 
enzyme responsible for maintaining breast cancer proliferation. CST6 did not require 
secretion or glycosylation to elicit its cell killing effects, suggesting an intracellular 
mode of action. Finally, we show that TBX2 and CST6 displayed reciprocal expression 
in a cohort of primary breast cancers with increased TBX2 expression associating 
with increased metastases. We have also noted that tumors with altered TBX2/
CST6 expression show poor overall survival. This novel TBX2-CST6-LGMN signaling 
pathway, therefore, represents an exciting opportunity for the development of novel 
therapies to target TBX2 driven breast cancers. 
 INTRODUCTION
TBX2 is a member of the T-box family of 
transcription factors, which play important roles in 
developmental gene regulation [1]. T-box proteins 
bind DNA and regulate gene expression through highly 
conserved 180-200 amino acid T-box motifs. TBX2 is 
an embryonically restricted gene normally expressed in 
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the milk ridge during the development of the duct system 
of the mammary gland in the mouse [1]. TBX2 was first 
linked to cancer through its ability to facilitate senescence 
bypass in Bmi-/- mouse embryo fibroblasts [2] and was 
found to be a potent immortalizing gene downregulating 
Cdkn2a (p19ARF, p14ARF in humans). TBX2 was also 
shown to bind to and repress the p21WAF1 promoter both 
in vitro and in vivo [3] and to have a role in maintaining 
proliferation and suppressing cell senescence in melanoma 
cells [4]. It promotes anchorage-independent growth and 
bypass of apoptotic pathways in adrenocortical carcinomas 
[5]. The Retinoblastoma protein Rb1 is another key 
tumor suppressor gene whose function is altered by 
TBX2 resulting in cell cycle perturbations [6]. We have 
previously shown addiction of TBX2-amplified cell lines 
to elevated TBX2 protein expression and that TBX2 
transcriptionally represses the breast tumor suppressor 
gene N-myc Down Regulated Gene 1 (NDRG1) through 
interaction with EGR1 to promote cell proliferation and 
inhibit cellular senescence [7]. Oncogene addiction is 
thought to arise from dependence on a specific oncogenic 
pathway due to deactivation of an analogous redundant 
pro-survival pathway [8]. The oncogene is therefore not 
required for normal growth prior to its aberrant activation. 
This is usually evident from the lack of addiction to the 
oncogene in cell lines derived from corresponding normal 
tissue [reviewed in [8]]. In addition, some oncogenic 
events can generate a requirement of secondary oncogenic 
addictions [8, 9].
Cystatin 6 (CST6), also called cystatin E/M, was 
first identified as a cysteine protease inhibitor which 
showed a significant downregulation in breast cancer 
mRNA samples compared to matched normal control 
mRNAs [10]. Cystatins constitute a large family of 
protease inhibitors known to target lysosomal cysteine 
proteases and Asparaginyl Endopeptidases (AEPs). CST6 
has been postulated to be a tumor suppressor gene in 
breast tissue [11], reducing breast cancer cell proliferation, 
migration, matrigel invasion, and adhesion to endothelial 
cells [12]. More recently, loss of CST6 expression 
has been reported in a number of other cancer types 
including cervical, glioma, prostate and gastric cancers 
[13],[14],[15],[16]. Loss of CST6 expression in breast 
cancers has been attributed to promoter hypermethylation 
[11]. CST6 has been shown to be important for skin 
differentiation which was shown to be disrupted in cst6-
deficient mice, accompanied by uncontrolled activity of 
a specific AEP called Legumain (LGMN) [17]. LGMN 
is a known oncogene, an indicator of poor prognosis in 
colorectal and breast cancers and has been reported to be 
overexpressed in the majority of human solid tumors [18], 
[19].
In this study we identify CST6 as a novel TBX2 
repressed target through a mechanism involving EGR1. 
We show that exogenous expression of wild-type CST6 
induces apoptotic effects in TBX2 expressing breast 
cancer cells but not in non-tumorigenic breast cells. 
CST6-induced apoptosis is dependent on inhibition of 
the protease LGMN since CST6 mutants lacking LGMN 
(but not cathepsin) inhibitory activity were also unable to 
induce apoptosis. We also demonstrate that the secretion 
or glycosylation of CST6 was not required for this cell 
killing effect. We conclude that CST6 represents an 
important barrier to breast tumorigenesis which is targeted 
and bypassed by TBX2 transcriptional repression and 
we discuss the implications of these findings for breast 
tumorigenesis and the potential for novel therapeutic 
opportunities.
RESULTS
CST6 was identified as a strongly repressed 
TBX2 transcriptional target in a microarray analysis of 
MCF7 cells following TBX2 siRNA knockdown (data 
not shown). Figures 1A and 1B show RqPCR values 
for TBX2 and CST6, respectively, following siRNA 
knockdown of TBX2 in three different breast cancer 
cell lines. CST6 was also upregulated in MCF7 cells 
following tetracycline-induced (-tet) expression of a 
truncated dominant negative TBX2 (DN-TBX2, Figure 
1C, Supplementary Figure S1.A), missing the putative 
C-terminal repression domain [7]. Conversely, CST6 was 
downregulated following exogenous expression of wild-
type TBX2 in U2OS cells (lacking endogenous TBX2 
expression, Supplementary Figure S1.B and S1.C). To 
help define mechanistically how TBX2 repressed CST6 
we generated a luciferase reporter construct of the CST6 
proximal promoter (-959/+30). This construct was TBX2-
responsive (Figure 1D), showing strong repression of 
luciferase following exogenous expression of TBX2 
in U2OS cells. Exonuclease mapping of the -959/+30 
reporter showed that even the shortest region (-101/+30 
upstream of the CST6 transcriptional start site) was TBX2 
responsive (Figure 1E).
Using transcription factor binding site prediction 
programs (such as TFSearch) we identified two putative 
TBX2 binding sites in the -959/+30 region. However, 
following SDM of both sites we observed no abrogation 
of TBX2 repression, indicating that they were not required 
(Figure 2A). We suspected that CST6 may be repressed 
by TBX2 through an EGR1-dependent mechanism 
similar to another characterized target NDRG1 (7). 
Accordingly, siRNA knockdown of EGR1 in MCF7 cells 
(Supplementary Figure S2.A) completely abolished the 
ability of TBX2 to repress the -959/+30 reporter (Figure 
2B), accompanied by upregulation of CST6 mRNA 
(Figure 2C). However, we could not definitively show 
exactly which EGR1 site was responsible since SDM of 
the four most conserved EGR1 sites did not completely 
abolish TBX2-mediated repression (Supplementary Figure 
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S2.B). We were, however, able to localize both TBX2 and 
EGR1 to the CST6 proximal promoter by ChIP assay 
(Figure 2D), with a region immediately upstream of the 
proximal promoter (-1150/-933) serving as an internal 
negative control. We could also show the requirement for 
EGR1 in this repression mechanism as siRNA knockdown 
of EGR1 (Supplementary Figure S2.C) resulted in a total 
loss of TBX2 recruitment to the CST6 promoter (Figure 
2E). Together these data show that TBX2 represses CST6 
through a proximal promoter region through an EGR1-
dependent mechanism.
We have previously shown that TBX2 expressing 
breast cancer cells were addicted to TBX2  and therefore 
acutely sensitive to TBX2 downregulation, resulting in 
dramatic growth inhibition and apoptosis [7]. We wanted 
to assess the contribution of CST6 re-expression to this 
cell-killing phenotype. Exogenous expression of CST6 
resulted in dramatic cell death in TBX2-expressing cells 
with non-tumorigenic cells totally unaffected (Figure 3A, 
viability decreased by up to 90%, Figure 3B). The most 
dramatic cell kill effect was observed in the OCUB-M 
cell line. This cell line expresses mutant p53 and is ERα 
negative. In our initial screen of breast cancer cells we 
found the OCUB-M cells to be amongst those having 
an aberrant overexpression of TBX2. Even though these 
cells do not appear to have TBX2 levels comparable with 
MCF7 cells [7], they appear to be clearly addicted to the 
expression of TBX2 to a far greater extent, displaying 
a more dramatic cell killing phenotype following 
CST6 expression. We noted that CST6-induced cell 
growth inhibition was due to apoptosis since exogenous 
expression resulted in PARP cleavage of MCF7 cells 
(Figure 3C) and caspase-3 cleavage of T47D could be 
detected as early as 24 hours post transfection (Figure 
3D). CST6 is known to be localized to lysosomes but 
we observed no loss of lysosomal integrity on specific 
lysosomal staining following CST6 overexpression in 
MCF7 cells (using LysoTracker Red DND-99 dye, Figure 
3E, with a matched western blot shown in Supplementary 
Figure S3.A) Autophagy is known to act as a prelude to 
apoptosis following specific stimuli [21], characterized 
by the accumulation of microtubule-associated protein 
1 light chain 3-phosphatidylethanolamine (LC3BII), a 
protein associated with the autophagosome membrane. 
The amount of LC3BII increased significantly upon CST6 
overexpression in MCF7 cells (Figure 3F) indicative of the 
presence of autophagy. We therefore conclude that CST6 
induces an autophagy related series of events culminating 
Figure 1: TBX2 represses the CST6 proximal promoter. (A) RqPCR analysis showing TBX2 mRNA levels in MCF7, T47D, and 
BT474 cells transiently transfected with TBX2 siRNA (TBX2si) or scrambled control (Scr). GAPDH mRNA was used for normalization. 
(B) RqPCR analysis showing CST6 expression of the same samples in (A). (C) RqPCR analysis showing CST6 expression in MCF7 cells 
stably transfected with a tetracycline responsive FLAG tagged Dominant Negative TBX2 (Flag DN-TBX2) with GAPDH mRNA used for 
normalization. (D) Luciferase reporter assay of U2OS cells transiently transfected with the indicated CST6 promoter constructs or empty 
vector (pGL3 basic), either in presence of an empty vector (pDEST) or a TBX2 expression construct (TBX2). (E) Luciferase reporter assay 
of U2OS cells transiently transfected with a series of CST6 promoter constructs generated by exonuclease mapping or empty vector (pGL3 
basic), either in the presence of pDEST or TBX2 expression constructs (TBX2). 
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in the apoptosis of breast cancer cells.
To compare cathepsin- versus AEP-inhibitory 
functions of CST6 for apoptosis induction we generated 
point mutants of CST6 previously shown to abrogate the 
respective inhibitory activities of CST6 [22]. Exogenous 
expression of FLAG-tagged wild-type CST6 (and a 
cathepsin inhibitory-defective point mutant (CST6-
W135A) both resulted in significant apoptosis whilst 
the LGMN inhibitory-defective mutant (CST6-N64A) 
showed a complete loss of cell killing activity in both 
MCF-7 and T47D cells (Figures 4A and 4D, respectively) 
quantified as approximately 80% and 60% (Figures 
4B and 4E). Western blotting confirmed that all three 
constructs showed equivalent expression (Figures 4C 
and 4F). LGMN activity assays in MCF-7 cells showed 
that while WT and CST6-W135A effectively inhibited 
LGMN activity, EV and the CST6-N64A mutant did 
not (Figure 4G). In contrast, the effect on Cathepsin B 
inhibition was weaker but the W135A mutant showed 
a clear reduction in Cathepsin B inhibition as expected 
(Figure 4H). Cathepsins (notably cathepsin B) have 
well described roles in proliferation and metastases. 
However, when we used the pan-cathepsin inhibitor, 
E-64-d, in the TBX2-expressing cell lines MCF7 and 
T47D we observed that complete inhibition of cathepsin 
activity did not result in any obvious growth difference 
or apoptosis (Supplementary Figure S4.A, quantified 
relative to control in S4.B), whilst a cathepsin B-specific 
assay showed that 10mM E-64-d resulted in complete 
inhibition of cathepsin B activity (Supplementary Figure 
S4.C). To specifically target cathepsin B an siRNA 
approach produced approximately a 90% knockdown 
(Supplementary Figure S4.D) but no corresponding cell 
growth inhibition (Supplementary Figures S4.E and 
S4.F) despite a corresponding 90% reduction in enzyme 
activity (Supplementary Figure S4.G). In fact cathepsin 
B knockdown actually resulted in the increased growth of 
MCF-7 cells, possibly reflecting the fact that it also plays a 
role in apoptosis via the Tumor Necrosis Factor α (TNFα) 
pathway.
The AEP (C-13) class of cysteine proteases 
contains only two proteins, namely, LGMN and 
glycosylphosphatidylinositol transamidase 8 (GPI8). 
Specifically targeting LGMN using three independent 
Figure 2: TBX2 represses CST6 through an EGR1-dependent mechanism. (A) Luciferase reporter assay of U2OS cells 
transiently transfected with an empty luciferase vector (pGL3-basic), a CST6 promoter construct (-959/+30), or -959/+30 with two putative 
TBX2 binding site mutations (-857 and -172, respectively) and co-transfected with an empty expression vector (pDEST) or a TBX2 
expression construct (TBX2). (B) Relative luciferase activity of pGL3-basic or a CST6 promoter construct (-959/+30) in U2OS cells, 
co-transfected in the presence of either pDEST or a TBX2 expression construct (TBX2) and each treated with Scrambled control (Scr) 
or EGR1 siRNA (EGR1si). (C) RqPCR analysis showing CST6 expression in MCF7 cells treated with EGR1si or Scr. (D) Endogenous 
ChIP assay showing recruitment of both TBX2 and EGR1 to a proximal region of the CST6 promoter (-153/+30) in MCF7 cells. A distal 
promoter region (-1150/-933) served as a negative internal control, a rabbit IgG was used to show specificity for the respective pull downs 
and a sample of 2.5% cell lysate prior to pulldowns was used as an input. (E) ChIP assay of MCF7 cells transiently transfected with EGR1 
siRNA (EGR1si) or scrambled control siRNA (Scr) showing recruitment of TBX2 and EGR1 to the CST6 promoter. The same negative 
controls were used as outlined in (D).
Oncotarget1613www.impactjournals.com/oncotarget
siRNA sequences, all produced significant reductions in 
LGMN mRNA (Figure 5A) coincident with a dramatic 
cell death phenotype (Figure 5B) of between 50-95% 
compared to scrambled control siRNA (Figure 5C). The 
efficacy of knockdowns reflected cell growth effects and 
knockdown of LGMN enzyme activities (Figure 5D). 
GPI8 knockdowns, however, (using two independent 
siRNAs, Figure 5E) failed to produce any significant 
apoptosis (Figure 5F, quantified <20% for both siRNAs 
in Figure 5G). Confirming that TBX2 expression levels 
Figure 3: CST6 induces apoptosis in a cancer-specific manner. (A) Crystal violet staining of MCF7, T47D, OCUB-M, MCF10A 
and HME1 cells transfected with either empty vector (EV) or the CST6 expression construct (CST6). The cells were grown for 6 days, 
stained with crystal violet to demonstrate cell viability. Matched Western blots showing CST6 expression compared to EV control with 
GAPDH antibody used as a loading control are also shown. (B) Crystal violet reabsorption of the plates stained in (A). (C) Western 
blot showing exogenous expression of CST6 in MCF7 cells collected over a 5 day time course alongside the corresponding EV and the 
consequent cleavage of PARP. GAPDH expression was used as a loading control. (D) Western blot analysis showing exogenous expression 
of CST6 in T47D cells collected over a 6 day time course alongside the corresponding EV and the consequent expression of full length 
caspase-3 (32kDa) and cleaved caspase-3 fragments (19kDa and 17kDa). Beta-tubulin expression was used as a loading control. (E) 
Immunofluorescence staining of MCF7 cells transiently transfected with either EV or CST6 expression construct and stained with 100nM 
Lysotracker. (F) Western blot analysis showing MCF7 cells transiently transfected with EV or CST6 expression construct (CST6), probed 
with a CST6, an LC3b i/ii antibody followed by a GAPDH antibody serving as a loading control. 
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indirectly controlled LGMN activity, we observed 
knockdown of TBX2 mRNA by siRNA (~40%) in MCF-7 
cells (Figure 5H) was accompanied by a similar inhibition 
of LGMN activity (Figure 5I). Together these data 
suggest that the mechanism through which CST6 induces 
apoptosis is due to its inhibition of LGMN activity and 
that TBX2 drives tumor growth through maintenance of 
LGMN activity.
Many Cystatins are known to be secreted suggesting 
that the principal mode of CST6 action is extracellular. 
Following transfection of MCF7 cells with a FLAG-
tagged CST6 we were able to detect two prominent 
forms of CST6 from cell media (Figure 6A). Whilst we 
could clearly visualize CST6 by immunofluroescence 
(IF) in directly transfected cells, we could not detect 
CST6 re-entry into naïve cells, even by incubating 
cells overnight with concentrated media (as shown by 
Western blotting, Figure 6A, or by IF, Figure 6B). There 
Figure 4: CST6 induces apoptosis through inhibition of asparaginyl endopeptidase activity. (A) Crystal violet staining of 
MCF7 cells transfected with empty vector (EV) or WT-FLAG-tagged CST6 (CST6 WT) or FLAG-tagged mutants CST6-N64A and CST6-
W135A. (B) Crystal violet reabsorption of the same samples as (A)(i)  (C) Western blot of samples in (A) probed with a FLAG antibody 
and a GAPDH antibody serving as a loading control. (D) Crystal violet staining of T47D cells transfected with either EV or Wild type 
(WT)-FLAG-tagged CST6 or FLAG-tagged mutants CST6-N64A and CST6-W135A. (E) Crystal violet reabsorption of the same samples 
as (D). (F) Western blot analysis of the same samples as (D) probed with a FLAG antibody and a GAPDH antibody serving as a loading 
control. (G) LGMN activity assay showing relative fluorescence units (RFU) plotted as a function of time for the same samples as (A). (H) 
Cathepsin B activity assay showing RFU plotted as a function of time for the same samples as (A).
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was also no evidence of cell killing observed following 
incubation with CST6-containing concentrated media 
(Supplementary Figures S5.A, S5.B and S5.C). We 
generated an N-terminal deletion mutant of CST6 lacking 
the signal peptide (CST6 del 1-28) which we could show 
was not secreted into media (Figure 6C) but was fully 
functional in cell killing (Figures 6D and E) indicating that 
CST6 secretion was not required for apoptosis. A LGMN 
activity assay of the lysate showed that CST6 del1-28 
lost partial ability to inhibit CST6 but was still be to kill 
cells efficiently (Figure 6F). Several Cystatins (such as 
Cystatin F) are known to be glycosylated, an event which 
facilitates their entry into neighboring cells [23]. However, 
a FLAG-tagged CST6 mutant N137A was equally 
expressed alongside wild-type CST6 in transfected cells 
(Figure 6G), equally proficient in killing expressing cells 
(Figures 6H and 6I) and retained full inhibitory activity 
(Figure 6J). Together these data show that CST6 does not 
require secretion, cellular re-entry or glycosylation for the 
induction of apoptosis. 
Figure 5: LGMN is the enzyme downstream of TBX2 and CST6 responsible for maintaining the proliferation of breast 
cancer cells. (A) RqPCR of LGMN siRNA knockdowns (LGMNsi#1-3) in MCF7 cells compared with cells treated with a scrambled 
(Scr) control siRNA. (B) The same samples as (A) stained with crystal violet 5 days post transfection. (C) Crystal violet reabsorption of 
MCF7 cells from plates shown in (A). (D) LGMN activity expressed as RFU as a function of time in matched protein samples in MCF7 
cells, treated with scrambled siRNA or the three different LGMN siRNAs #1 – #3 outlined in A. (E) RqPCR quantification of GPI8 siRNA 
knockdowns (GPI8si#1-&2) in MCF7 cells compared with cells treated with a scrambled (Scr) control siRNA. (F) Same samples as (E) 
stained with crystal violet 5 days post transfection. (G) Crystal violet reabsorption values of MCF7 cells shown in (E). (H) RqPCR showing 
TBX2 expression in MCF7 cells following knockdown with a scrambled siRNA (SCR) control or a TBX2 specific siRNA (TBX2si), 
normalized to endogenous levels of GAPDH. (I) LGMN activity assay matched to the experiment in (H).
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In order to see if our cell line data corresponded with 
tumor data we carried out immunohistochemical staining 
on Tissue Microarrays generated from a small cohort of 
breast tumors. In agreement with the cell line data we 
noted that CST6 expression inversely correlated with 
TBX2 expression ( -0.365,p-value =0.005). We observed 
that tumors expressing TBX2 showed an increased 
tendency towards metastasis while CST6 expressing 
tumors showed a trend towards a decrease in metastatic 
potential. In small subset of five TBX2-expressing tumors 
where chemoresponse data was available, we observed a 
modest trend towards chemoresistance. We also compared 
our data with the larger publically available datasets from 
The Cancer Genome Atlas (TCGA). In line with previous 
findings, CGH studies showed that TBX2 appeared to 
be amplified in approximately 10% of breast cancers. 
Microarray and RNAseq studies showed a consequent 
upregulation of TBX2 mRNA in these tumors (dataset 
Figure 6: CST6 does not require secretion or glycosylation to inhibit LGMN activity. (A) Western blot showing expression of 
FLAG-CST6 in MCF7 cells transfected with empty vector (EV) and or CST6 expression vector (lanes 1 and 2), concentrated media (lanes 3 
and 4) and naive cells treated with a 1:2 dilution of EV and CST6 concentrated conditioned media (lanes 5 and 6), and a 1:4 dilution of EV 
and CST6 (lanes 7 and 8). (B) Immunofluorescence (10X) of MCF7 cells transfected with FLAG-tagged CST6 (left) and naive cells treated 
with 10X concentrated conditioned media for 24 hours post transfection and stained with FLAG antibody at 10X magnification (right). (C) 
Western blot showing conditioned media and cell lysates from MCF7 cells transfected with either EV or FLAG-CST6 or a FLAG tagged 
version of CST6del(1-28). Samples were collected 24 hours post transfection. Beta-tubulin was used as a loading control. (D) Crystal 
violet staining of viable cells 6 days post transfection of MCF7 cells with either EV or FLAG-CST6 or the mutant CST6 lacking the signal 
peptide CST6 del(1-28).  (E) Crystal violet reabsorption of the samples outlined in (D) (F) LGMN activity assay of conditioned medium 
matched to the experiment (D) (G) Western blot showing glycosylated and unglycosylated forms of CST6 in MCF7 cells transfected with 
FLAG-CST6 or the glycosylation site mutant CST6 (N137A-CST6) 24 hours post transfection. Beta-tubulin was used as a loading control. 
(H) Crystal violet staining of MCF7 cells 6 days post transfection with either EV or WT-FLAG -CST6 or the glycosylation mutant form 
of CST6 (N137A). (I) Crystal violet reabsorption from the transfections outlined in (H). (J) LGMN activity assay of cell lysates matched 
to the experiment (H).
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from [24], and a provisional dataset currently in press, 
Nature). CST6 expression, if altered, was generally 
downregulated observed in about 5% of the tumors in both 
datasets. Tumors with altered TBX2 and CST6 expression 
also showed very poor overall survival by microarray 
studies (Supplementary figure S6.A). 
DISCUSSION
In this study we show for the first time that 
the putative breast tumor suppressor gene CST6 is 
consistently repressed by the oncogenic transcription 
factor TBX2 through a mechanism involving EGR1. 
Exogenous expression of wild-type CST6 in TBX2 
expressing breast cancer cells resulted in significant 
apoptosis whilst non-tumorigenic breast cells remain 
unaffected. We show through a number of alternative 
approaches (siRNA knockdowns, pan-cathepsin inhibition 
and SDM) that CST6-induced apoptosis is due to its 
ability to specifically inhibit the AEP protease LGMN 
and not cathepsin-type proteases. Accordingly, LGMN 
activity assays confirmed that the observed CST6 growth 
effects were consistent with specific inhibition of LGMN. 
Whilst both LGMN and CST6 are known to be secreted 
proteins, neither the secretion nor glycosylation of CST6 
was required for its cell killing function. We conclude that 
through its ability to counteract LGMN activity, CST6 
represents an important barrier to breast tumorigenesis, 
a function which is abrogated by TBX2 transcriptional 
repression. These findings have obvious implications for 
breast tumorigenesis and highlight potential therapeutic 
opportunities for the treatment of TBX2 overexpressing 
or CST6-deificient breast cancers.
Aberrant TBX2 expression is likely to be just one of 
many pathways leading to loss of CST6 in cancers. CST6 
loss in breast cancers has been shown to be associated with 
loss of both ERα and the progesterone receptor [25]. One 
of the mechanisms of CST6 downregulation is promoter 
methylation which was shown to be strongly associated 
with poor prognosis in operable breast cancers [26]. Indeed 
CST6 was amongst the 10 most hypermethylated genes in 
comparisons between breast cancers and matched normal 
breast tissues [27]. The mechanism responsible for CST6 
promoter methylation is still unknown but it has been 
reported to be associated with aberrant AKT1 activation 
and disablement of the negative AKT regulator INPP4B 
in breast epithelial cells [28]. It has also been shown 
that hypermethylator breast cell lines which overexpress 
total DNA methyltransferase (DNMT) activity (and in 
particular DNMT3b) had significantly reduced levels of 
a number of genes including CST6  [29]. Whilst there is 
no evidence for TBX2 recruitment of DNMTs to target 
promoters, the C-terminal region of TBX2 has been 
shown to coimmunoprecipitate with HDAC1 in mouse 
melanoma cells to target repression of the key cell cycle 
inhibitor p21WAF1 [4]. TBX2 is also known to interact with 
histone H3 and to colocalize with regions of pericentric 
heterochromatin [30]. We hypothesize that TBX2 acts 
to target EGR1-responsive genes to facilitate histone 
methylation and deacetylation and to enforce a non-
permissive heterochromatin microenvironment around 
promoters such as CST6. 
LGMN expression is known to correlate with a 
lower rate of apoptosis, and increased metastasis and 
tumor invasion [31]. Whilst it correlates with poor 
prognosis in multiple tumor types [18, 19, 32, 33], the role 
of LGMN in promoting tumorigenesis remains a mystery. 
One downstream pathway which may be involved is the 
Matrix Metalloproteinase 2 (MMP2) pathway. LGMN 
is known to cleave pro-MMP2 leading to its activation, 
even in the presence of its natural inhibitor TIMP-2 [34]. 
LGMN has been shown to colocalize with integrins, at 
the cell surface ‘invadopodia’ of invading cells where 
it participates in the cleavage and activation of MMP2 
to help drive invasion and metastasis [31]. We propose 
that the loss of CST6 expression observed in breast and 
many other solid tumor types would lead to elevated 
LGMN activities, elevated MMP2 signaling and enhanced 
proliferation, invasion and metastasis, reflecting the poor 
prognosis of LGMN expressing tumors.
Whilst the hallmarks of cancer are multifactorial, 
there are numerous examples demonstrating how 
aberrations in key oncogenes are clear driver events in 
cancer pathogenesis. Activation of other oncogenes may 
be rate-limiting events responsible for specific phases of 
cancer development such as initial transformation events 
whilst later events such as the progression or maintenance 
of tumor viability may require completely different 
oncogenic mechanisms [35]. Additionally, tumor cells 
may also be addicted to particular biological processes 
such as oncogenic Ras-mediated transformation and tumor 
growth being dependent on autophagy [36]. From a breast 
cancer perspective, a prime example of how to effectively 
target oncogene addiction is demonstrated by the success 
of trastuzumab treatment of HER2 positive breast cancers. 
The apparent ‘addiction’ to LGMN for cell survival that 
we have observed in breast cancer cell lines and the high 
activity of LGMN previously reported across a range of 
cancer types has made targeting this enzyme an attractive 
prospect for the development of novel inhibitors. Potent 
and selective LGMN inhibitors of Schistosoma mansoni 
and pig kidney LGMN have previously been developed 
[37]. Cell permeable, potent inhibitors have also been 
designed against recombinant mouse LGMN [38]. There 
have been a number of alternative therapeutic strategies 
developed to exploit the hyperactivity of LGMN in 
different tumor types. For example, elevated tumor LGMN 
activity has recently been used as the basis for developing 
LGMN-cleavage strategies to activate Auristatin prodrugs 
[39], in addition to more conventional chemotherapeutic 
agents such as etoposide [40] or doxorubicin [31]. The 
doxorubicin prodrug completely arrested the growth of 
Oncotarget1618www.impactjournals.com/oncotarget
a variety of neoplasms, including multidrug-resistant 
tumors in vivo and significantly extended survival 
without evidence of myelosuppression or cardiac toxicity 
[41]. In addition liposomal nanoparticles encapsulating 
doxorubicin coupled to a LGMN inhibitor showed high 
potency, good stability and little cross reactivity with other 
cysteine proteases [42]. The prevalence of CST6 loss and 
LGMN hyperactivation across many tumor types therefore 
represents an exciting opportunity for the development of 
novel targeted therapies.
In summary, we have identified a novel pathway 
regulated by the breast cancer oncogene TBX2. We show 
for the first time that TBX2 mediated transcriptional 
repression of CST6 is an important event for maintaining 
the tumorigenesis of a subset of breast cancers, through 
aberrant activation of the protease LGMN. These findings 
provide an opportunity for the development of specific 
targeted treatment for multiple tumor types, linking an 
imbalance of Oncogene-Tumor Suppressor expression 
(TBX2-CST6) with a defined enzymatic hyperactivity 
(LGMN). We suggest that the development of cell 
permeable LGMN inhibitors may be an important advance 
in the clinical management of poor prognosis breast 
cancers and multiple other tumor types.
MATERIALS AND METHODS
Maintenance of cell lines:
Full details of the maintenance of the MCF7, 
T47D, BT474, U2OS and MCF7-DN cells are provided 
in [7]. OCUB-M cells were maintained in DMEM media 
supplemented with 10% fetal calf serum, 1mM sodium 
pyruvate (Life Technologies, Inc, Paisley, UK). MCF10A 
cells were cultured in DMEM:F-12 1:1 phenol red 
free medium, 5% Horse Serum, 20ng/ml EGF, 500ng/
mlHydrocortisone, 100ng/ml Cholera toxin, 10ng/
ml insulin and 1mM L-glutamine. HME-1 cells were 
cultured in Medium 171 supplemented with an MGEM 
bullet kit (Cascade Biologicals, Life Technologies) and 5 
micrograms/ml transferrin (Sigma-Aldrich, Dorset, UK). 
All were grown in 5% CO2 in a humidified incubator. For 
E-64d treatment of cells, a stock solution was prepared 
at 5 mg/ml, MeOH:H2O (1:1) and cells were treated at a 
final concentration of 10μM.
Luciferase assay:
Luciferase assay was carried out in U2OS cells 
transfected with control (pGL3-basic empty vector) or 
the vector containing the CST6 promoter constructs. The 
assay was carried out as previously described [7].
Chromatin immunoprecipitation:
This assay was carried out in MCF7 cells. The 
method is described in [7]. Promoter primers were 
designed against a proximal region and a region 
approximately 1000bp upstream of the translational start 
site as a non-specific negative control (primer sequences 
are detailed below).
Enzyme activity assays: 
MCF7 and T47D cells were harvested in PBS at 4ºC. 
Cell pellets were re-suspended in lysis buffer (40mM citric 
acid, 121mM NaH2PO4, 1mM EDTA, 0.1% CHAPS, 
1mM DTT, pH5.8) on ice for 15 mins, syringed through 
a 21-gauge needle and frozen at -80ºC. Cells were then 
centrifuged at 16000g for 20 mins at 4ºC and the protein 
concentration in the supernate was determined. Activity 
of cellular enzyme was measured by diluting lysate in 
assay buffer (40mM citric acid, 121mM NaH2PO4, 1mM 
EDTA, 1mM DTT, pH5.8). The reaction for LGMN was 
initiated by addition of 10 microlitres of the substrate 
Z-Ala-Ala-Asn-MCA (Peptides Institute, Osaka, Japan) 
to a final concentration of 10 micromolar substrate. The 
reaction for Cathepsin B was initiated by the addition of 
10 microlitres of the substrate Ac-RR-AFC (Bio Vision, 
San Francisco, CA, USA).The plates were read on the 
Synergy 4 microplate reader (Biotek, Bedfordshire, UK) at 
37 ºC and the readings were recorded at excitation 360nm 
and emission 460nm every two minutes. Data was blanked 
against a substrate only well in Gen 5 software.  For the 
cell free assay, rLGMN (R&D systems, Abingdon, UK) 
was activated in the presence of 50mM NaOAc,100mM 
NaCl, pH 4.0 for 2 hours at 37ºC. 500nmol of activated 
rLGMN was diluted in 10mls of assay buffer.
Preparation of cells, reagents, western blotting 
procedures are described in [43], Real Time quantitative 
PCR (RqPCR), siRNA treatments and Chromatin 
Immunoprecipitation (ChIP) assays in [7] and cell 
proliferation assays in [44]. Sequences of RqPCR, 
luciferase, and ChIP primers as well as antibody sources 
and dilutions are listed in supplementary information. The 
details for construction of the tissue microarray blocks 
were described previously [45].
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